- Home
- PBFS vs ESPR Comparison
PBFS vs ESPR Comparison
Compare PBFS & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- ESPR
- Stock Information
- Founded
- PBFS 1889
- ESPR 2008
- Country
- PBFS United States
- ESPR United States
- Employees
- PBFS N/A
- ESPR N/A
- Industry
- PBFS Banks
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- ESPR Health Care
- Exchange
- PBFS Nasdaq
- ESPR Nasdaq
- Market Cap
- PBFS 277.5M
- ESPR 319.2M
- IPO Year
- PBFS N/A
- ESPR 2013
- Fundamental
- Price
- PBFS $11.45
- ESPR $2.12
- Analyst Decision
- PBFS
- ESPR Buy
- Analyst Count
- PBFS 0
- ESPR 4
- Target Price
- PBFS N/A
- ESPR $8.17
- AVG Volume (30 Days)
- PBFS 28.9K
- ESPR 4.8M
- Earning Date
- PBFS 11-12-2024
- ESPR 11-07-2024
- Dividend Yield
- PBFS N/A
- ESPR N/A
- EPS Growth
- PBFS N/A
- ESPR N/A
- EPS
- PBFS 0.72
- ESPR N/A
- Revenue
- PBFS $78,364,000.00
- ESPR $295,451,000.00
- Revenue This Year
- PBFS N/A
- ESPR $198.22
- Revenue Next Year
- PBFS N/A
- ESPR $25.83
- P/E Ratio
- PBFS $16.02
- ESPR N/A
- Revenue Growth
- PBFS N/A
- ESPR 187.12
- 52 Week Low
- PBFS $7.97
- ESPR $1.08
- 52 Week High
- PBFS $11.86
- ESPR $3.40
- Technical
- Relative Strength Index (RSI)
- PBFS 57.80
- ESPR 50.12
- Support Level
- PBFS $11.36
- ESPR $1.87
- Resistance Level
- PBFS $11.85
- ESPR $2.60
- Average True Range (ATR)
- PBFS 0.30
- ESPR 0.17
- MACD
- PBFS 0.01
- ESPR -0.01
- Stochastic Oscillator
- PBFS 46.34
- ESPR 34.25
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting, and Insurance.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.